{"id":"W4395689019","doi":"10.1038/s41375-024-02254-2","title":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"MSD K.K.; Bristol-Myers Squibb Canada; Sanofi-Aventis Korea Company; Servier; Miltenyi Biotec; Takeda Pharmaceutical Company; AbbVie; Janssen Pharmaceuticals; Gilead Sciences; Roche; Novartis; Merck; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Falk Foundation","keywords":"Mantle cell lymphoma; Medicine; Bortezomib; Leukocytopenia; Internal medicine; Cytarabine; Rituximab; Autologous stem-cell transplantation; Neutropenia; Oncology; Gastroenterology; Surgery; Chemotherapy; Multiple myeloma; Lymphoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003576792,0.001280339,0.001921633,0.000485028,0.000327837,0.000914581,0.0008726806,0.001125499,0.00289381],"category_scores_gemma":[0.002396767,0.0005696969,0.001466339,0.0003575273,0.001469666,0.0009575932,0.0005620388,0.003000003,0.0003955445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007397207,"about_ca_system_score_gemma":0.0009519046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006159742,"about_ca_topic_score_gemma":0.001725747,"domain_scores_codex":[0.9982678,0.001322893,0.00008312694,0.0001484682,0.00006622593,0.0001113722],"domain_scores_gemma":[0.9985233,0.0005658642,0.0003161501,0.000124766,0.00005308095,0.0004168337],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9704685,0.009155722,0.0008198144,0.0001987246,0.0004746673,0.00001971265,0.00004022216,0.0003593085,0.002464675,0.00008911039,0.000254387,0.01565519],"study_design_scores_gemma":[0.841211,0.1546136,0.001852896,0.00001602664,0.0003460137,0.00003224166,0.00001835656,0.0005661125,0.0008003946,0.0001352845,0.000394793,0.00001330514],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955398,0.001709085,0.0003288897,0.0003542096,0.0002235397,0.001121136,0.0001963849,0.00003003955,0.0004967445],"genre_scores_gemma":[0.9945816,0.0009356751,0.001183592,0.0004722667,0.0003753311,0.001168624,0.0004050814,0.000009314416,0.0008685063],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003576792,"threshold_uncertainty_score":0.01891607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01898169825617816,"score_gpt":0.2830004427703793,"score_spread":0.2640187445142012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}